EUVIMEDEUVIMED entdecken
Leserbrief

Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration

Gai Liang, Qu Zhang iD, Mengting Yuan iD

Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3281-3281

DOI: 10.1200/jco-26-00911 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Gai Liang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gai Liang, MD, Qu Zhang, MD; and Mengting Yuan, MM, Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong Univers…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Gai Liang, MD, Qu Zhang, MD; and Mengting Yuan, MM, Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Qu Zhang, Mengting Yuan

Zitieren

APA

Liang, G., Zhang, Q., & Yuan, M. (2026). Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration. Journal of Clinical Oncology, 44(33), 3281-3281. https://doi.org/10.1200/jco-26-00911

Vancouver

Liang G, Zhang Q, Yuan M. Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration. Journal of Clinical Oncology. 2026;44(33):3281-3281. doi:10.1200/jco-26-00911

BibTeX
@article{Liang2026,
  author = {Liang, Gai and Zhang, Qu and Yuan, Mengting},
  title = {Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {33},
  pages = {3281--3281},
  doi = {10.1200/jco-26-00911}
}
Kostenlos starten →